IO Biotech (NASDAQ:IOBT) announced on Monday that patients with skin tumors who received its lead cancer vaccine candidate, Cylembio, with Merck’s (NYSE:MRK) anti-PD-1 therapy, Keytruda, lived longer ...

IO Biotech said on Monday its experimental cancer vaccine, in combination with Merck's Keytruda, showed improvement in a late-stage study goal, but was not statistically significant. It was testing ...

Women with advanced form womb cancer have been given fresh hope after a new treatment was given the green light for ...

Novo Nordisk, GSK and others need to replenish their pipelines to replace drugs coming off patent. In the past, buying a promising biotech required paying a 100% premium. But high interest rates and ...

China’s drugmakers are racing to roll out cheaper or more innovative alternatives. Read more at straitstimes.com. Read more ...

The system for compensating people injured by vaccines needs significant reform. But the health secretary could alter it in ...